Navigation Links
Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
Date:11/1/2010

EAST NORRITON, Pa., Nov. 1, 2010 /PRNewswire-FirstCall/ -- Tengion, Inc. (Nasdaq: TNGN) today provided a business update and reported its financial results for the third quarter ended September 30, 2010.

"We recently achieved a major milestone with the implantation of our Neo-Urinary Conduit in the first bladder cancer patient. We and our investigators believe that this first successful implant will facilitate future enrollment," stated Steven Nichtberger, M.D., Tengion President and CEO.  "We are also making significant progress in our kidney program.  Our scientists have now published or presented consistently positive data demonstrating stabilization and preservation of kidney function in four different animal models of kidney failure, including early data from a large animal model of chronic kidney disease.  We look forward to presenting additional data at scientific sessions next month."

Neo-Urinary Conduit Bladder Cancer Trial - Clinical UpdateThe Company's Neo-Urinary Conduit was recently implanted in the first patient as part of the ongoing initial clinical trial evaluating the Company's lead product candidate in bladder cancer patients requiring a urinary diversion following bladder removal.

The implantation of the first patient with the Neo-Urinary Conduit demonstrates the Company's ability to successfully procure an appropriate fat biopsy, ship the biopsy, isolate and expand selective regenerative cells to manufacture the Neo-Urinary Conduit, release the final product within quality control specifications, ship the final product to the hospital and have the Neo-Urinary Conduit implanted using the intended surgical procedure.

Neo-Kidney Augment Program UpdateThe Neo-Kidney Augment is the Company's lead preclinical program and is intended to prevent or delay the need for dialysis or kidney transplant by increasing functional
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
5. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
8. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
9. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... DIEGO , Aug. 26, 2014  Sorrento ... a late-stage clinical oncology company developing new treatments ... that it has received funding to advance an ... potential treatment of IPF, which affects more than ... the lungs increases and patients gradually lose the ...
(Date:8/26/2014)... , Aug. 26, 2014 MNX ... that it has renewed a multi-year contract providing ... the third largest spinal device company in the ... medical device industry is well suited to MNX,s ... that every shipment involves a surgeon, surgical team ...
(Date:8/26/2014)... DIEGO , Aug. 26, 2014 Profil ... research organization (CRO) focused on diabetes and obesity, announced ... completion of more than 200 phase I – IIa ... the treatment of type 1 and type 2 diabetes. ... of research is what it represents for the public ...
Breaking Medicine Technology:Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) 2Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) 3MNX Global Logistics renews multi-year contract with NuVasive, Inc. 2Profil Institute Reaches Milestone in Early Phase Clinical Research for Diabetes 2Profil Institute Reaches Milestone in Early Phase Clinical Research for Diabetes 3
... Improvement With Every-Four-Week Subcutaneous SIMPONI Despite Previous Medication ... June 9 A new analysis demonstrated that ... severely active rheumatoid arthritis (RA) who had prior ... received subcutaneous injections of SIMPONI(TM) (golimumab) once every ...
... in June Issue of Circulation , , SILVER ... Corporation (Nasdaq: UTHR ) and Eli Lilly ... the results of a pivotal 16-week study showing that ... improved exercise capacity and improved time to clinical worsening ...
Cached Medicine Technology:New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 2New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 3New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 4New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 5New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 6New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 7New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 8New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 9New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 10Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 2Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 3Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 4Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 5Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 6
(Date:8/27/2014)... August 27, 2014 Casey Diekman, assistant ... Technology (NJIT), is helping to gain greater insight into ... life. , Evolution has harmonized the behavior of humans ... that include the cycle of light and dark experienced ... clock controls hormone production related to natural patterns of ...
(Date:8/27/2014)... California (PRWEB) August 27, 2014 In My ... “Journey Candle Collection” to provide a growing number of women ... scent-based tool for goal setting and relaxing at the same ... soy candles, uses scent memory and visualization to help women ... their life each time they light a candle and enjoy ...
(Date:8/27/2014)... 2014 PartnerTech Inc ., ... major systems integration and electronics manufacturer, announces a ... the first U.S. designed and manufactured whole body ... combination of manufacturing expertise, location, flexibility, and speed-to-market ... headquartered in Atlanta, GA, offers a whole body ...
(Date:8/26/2014)... 2014 Hearing aids are not ... for plan holders to determine what their hearing care benefits ... several additional health plans and has published benefit details on ... . , The following is a list of insurances ... provider: , NYSHIP/ NYS Empire Plan - Hearing Aid Benefit ...
(Date:8/26/2014)... Leelanau Peninsula, MI (PRWEB) August 27, 2014 ... Stompede event is a fabulous time to visit the ... providing a magnificent backdrop to wine tasting fun in ... 7, 2014. , Kicking off the festivities is an ... Saturday at Ciccone Vineyards in Suttons Bay. A unique ...
Breaking Medicine News(10 mins):Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 2Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 3Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 4Health News:In My Solitude Unveils Eco Candle Line That May Improve Performance 2Health News:PartnerTech Inc. and Impact Cryotherapy Announce Made in America Manufacturing Initiative 2Health News:PartnerTech Inc. and Impact Cryotherapy Announce Made in America Manufacturing Initiative 3Health News:East End Hearing of Long Island Now Participating in Many Local Health Plans 2Health News:East End Hearing of Long Island Now Participating in Many Local Health Plans 3Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers One-of-a-Kind Walk or Run Through the Vineyards for Walkers, Runners and Wine Tasting Spectators Alike 2Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers One-of-a-Kind Walk or Run Through the Vineyards for Walkers, Runners and Wine Tasting Spectators Alike 3
... the latest issue of the journal Antimicrobial Agents and ... occur in the human saliva can lead to new ... in children., ,Researchers at the University of Washington ... between dental caries (tooth decay) prevalence in children and ...
... been known to be associated with health hazards ... But it is known not until recently that ... exposure to mineraloil., ,The exact causative factor ... genetic, hormonal factors and environmental fcators have been ...
... doubled to 1 million worldwide and tripled in Africa and Asia. ... AIDS. Though, there is a immense increase in antiretroviral // treatment, ... goal to treat 3 million people by 2005, will never happen ... of those in Africa and 14% of those in Asia have ...
... control cream and a potent neurotoxin, used by Hollywood ... derived form a bacteria, Clostridium botulinum, that causes food ... this form of neurotoxin is playing an important role ... is exploring basic nerve cell function, minute changes that ...
... general health of people. , ,With health consciousness ... for improving health // status has considerably increased. The ... would be dependent to a large scale on the ... plants that the body uses to make vitamin A. ...
... teeth, called dentigerous cysts, may be harmless to the tooth ... head and neck area., ,Dentigerous cysts are painless, considered ... tooth eruption. However, head and neck specialists have recently encountered ... neck infections or as a deep neck space abscess. , ...
Cached Medicine News:Health News:B-Carotene Increases Oral Cancer Risk In Smokers 2Health News:Dental Cysts Can Cause Infections In Head And Neck 2
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: